Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor...

Area of Science:

• Oncology
• Nephrology
• Translational Medicine

Background:

• Renal cell carcinoma (RCC) exhibits significant heterogeneity, impacting treatment response and therapeutic decisions.
• Recent advances in advanced/metastatic RCC treatment include immunotherapy combinations, now standard of care.
• These advanced treatments, while effective, pose tolerability issues and negatively affect patient quality of life.

Purpose of the Study:

• To review the current state of kidney cancer treatment, focusing on immunotherapy and anti-angiogenesis tyrosine kinase inhibitors (TKIs).
• To identify specific patient subgroups within advanced RCC for whom TKI monotherapy is an appropriate frontline treatment.
• To establish criteria for selecting TKI monotherapy to prevent overtreatment and minimize treatment-related toxicity.

Main Methods:

• Expert panel discussion on the state-of-the-art in kidney cancer management.
• Review of clinical trial data, including subgroup and post hoc analyses.
• Focus on the efficacy and tolerability of anti-angiogenesis TKI monotherapy versus combination therapies.

Main Results:

• Immunotherapy combinations offer improved outcomes but are associated with significant toxicity.
• Not all patients equally benefit from current standard-of-care immunotherapy combinations.
• TKI monotherapy can be a sensible frontline option for carefully selected RCC patient subgroups.

Conclusions:

• TKI monotherapy represents a viable and less toxic frontline option for specific RCC patient profiles.
• Personalized treatment selection is crucial to balance efficacy with patient quality of life.
• Avoiding overtreatment and unnecessary toxicity is paramount in managing advanced or metastatic RCC.